Business
MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance
First quarter 2026 total revenue of $9.7 million, including $6.2 million of core revenue and $3.4 million of SPL Program-related revenue Reiterates 2026 revenue guidance of $30-32 million; with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million MaxCyte’s Board authorized a $10 million share repurchase program ROCKVILLE, Md., May 12, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling
About this update from Maxcyte, Inc.
[{"type":"image","alt":"MaxCyte, Inc","displaySize":"","headline":null,"caption":"MaxCyte, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":45,"url":"https://media.zenfs.com/en/globenewswire.com/18aaaba351d9f5c2181ef7acd6cea89a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/WYwJtM4XDMnm8G2fGhEvjA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYzO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/18aaaba351d9f5c2181ef7acd6cea89a","width":300,"height":45},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/WYwJtM4XDMnm8G2fGhEvjA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYzO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/18aaaba351d9f5c2181ef7acd6cea89a","width":300,"height":45}},"lazy":false},{"type":"text","content":"First quarter 2026 total revenue of $9.7 million, including $6.2 million of core revenue and $3.4 million of SPL Program-related revenue","length":136,"tagName":"p"},{"type":"text","content":"Reiterates 2026 revenue guidance of $30-32 million; with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million","length":154,"tagName":"p"},{"type":"text","content":"MaxCyte’s Board authorized a $10 million share repurchase program","length":65,"tagName":"p"},{"type":"text","content":"ROCKVILLE, Md., May 12, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its first quarter ended March 31, 2026 financial results and reiterated its 2026 guidance.","length":369,"tagName":"p"},{"type":"text","content":"“We are pleased with our performance in the first quarter, and remain confident in our full year guidance,” said Maher Masoud, President and CEO of MaxCyte. “Our core revenue from partners and customers was in line with our expectations for both our ExPERT electroporation platforms and SeQure services. The SPL portfolio continues to advance in the clinic, including a clinical customer that began dosing patients in a registrational study in the first quarter, and we remain confident additional customers will initiate registrational trials this year. Further, our SPL portfolio remains strong and spans a broad range of modalities and indications. MaxCyte remains extremely...